Between October 1993 and March 1999, 29 patients with CML who were ineligible for allogeneic BMT underwent PBSC harvest using idarubicin, cytarabine and G-CSF. In 9/29 (31%) patients all collected stem cells were Ph-negative, and 15/29 patients' (52%) collections were substantially (Ͼ95%) Ph-negative. The proportion of patients from whom Ph-negative stem cells were obtained was similar between patients who had, or had not, received prior ␣IFN. Fifteen patients in chronic phase (median age 45) proceeded to PBSCT following busulphan 16 mg/m 2 and cyclophosphamide 120 mg/m 2 . Nine of the 13 patients who had failed to respond to prior ␣IFN proceeded to stem cell transplantation as soon as was feasible and six of the newly diagnosed patients were transplanted after failing to achieve a cytogenetic response after a minimum of 12 months on ␣IFN following progenitor cell harvest. The median number of days to neutrophils Ͼ0.5 and platelet Ͼ50 was 18 (range 13-69) and 28 (range 13-234), respectively. There was no procedure-related mortality. At median follow-up of 2.3 years post autograft 10 of 15 patients remain alive and in chronic phase. Overall survival for all 27 patients at 5 years after initial diagnosis is 70% and median survival from diagnosis 7.3 years. Survival for ␣IFN non-responders who were transplanted is 74% at 5 years from diagnosis and 75% at 3 years from transplant. Cytogenetic analysis performed 3 months post transplant demonstrated one patient with a complete cytogenetic response, seven with a partial response and three with no response. Six patients remain partially Ph-negative, with one major CR. Survival for all patients in the protocol is favourable compared with conventional therapy and is particularly encouraging following PBSCT for ␣IFN non-responsive patients. Patients not responding to ␣IFN can be induced into Ph-negativity with PBSCT but this may not always be sustainable. There seems to be no obvious disadvantage in harvesting stem cells after prior exposure to ␣IFN, providing an adequate ␣IFN-free
. Nine of the 13 patients who had failed to respond to prior ␣IFN proceeded to stem cell transplantation as soon as was feasible and six of the newly diagnosed patients were transplanted after failing to achieve a cytogenetic response after a minimum of 12 months on ␣IFN following progenitor cell harvest. The median number of days to neutrophils Ͼ0.5 and platelet Ͼ50 was 18 (range 13-69) and 28 (range 13-234), respectively. There was no procedure-related mortality. At median follow-up of 2.3 years post autograft 10 of 15 patients remain alive and in chronic phase. Overall survival for all 27 patients at 5 years after initial diagnosis is 70% and median survival from diagnosis 7.3 years. Survival for ␣IFN non-responders who were transplanted is 74% at 5 years from diagnosis and 75% at 3 years from transplant. Cytogenetic analysis performed 3 months post transplant demonstrated one patient with a complete cytogenetic response, seven with a partial response and three with no response. Six patients remain partially Ph-negative, with one major CR. Survival for all patients in the protocol is favourable compared with conventional therapy and is particularly encouraging following PBSCT for ␣IFN non-responsive patients. Patients not responding to ␣IFN can be induced into Ph-negativity with PBSCT but this may not always be sustainable. There seems to be no obvious disadvantage in harvesting stem cells after prior exposure to ␣IFN, providing an adequate ␣IFN-free Allogeneic BMT is the only currently available curative option for CML, 1,2 but the majority of patients will be ineligible due to chronological age or absence of an HLAidentical donor. In addition, procedural-related mortality is relatively high.
There is evidence that patients with CML have residual Ph-negative haemopoiesis, at least in the early stages of the disease, which is presumed to be non-leukaemic. 3 As a result, high-dose chemotherapy followed by unmanipulated or ex vivo cultured autologous stem cell transplantation in patients with CML may result in transient Ph-negative haemopoiesis and encouraging survival durations, particularly if followed by ␣IFN therapy. [4] [5] [6] Following administration of myelosuppressive chemotherapy to patients with CML, progenitor cells appear in the peripheral blood. In the early stages of regeneration these cells may be substantially Ph-negative while still capable of supporting multi-lineage haemopoiesis in long-term culture and supporting haemopoietic engraftment in patients conditioned with high-dose chemotherapy. 7, 8 With the assistance of G-CSF these cells may be harvested from the peripheral blood by leukapheresis and used for subsequent transplantation. [8] [9] [10] ␣IFN prolongs chronic phase and overall survival in patients with CML not undergoing high-dose therapy. [11] [12] [13] [14] Patients achieving a cytogenetic response to ␣IFN survive longer than those who do not and ␣IFN is the treatment of choice for patients who achieve a major or complete cytogenetic response due to potentially long survival (9 years in low-risk patients). 15 Median survival for patients who fail to achieve a good cytogenetic response to ␣IFN is around 40 months. 12, 13, 16 Therefore, failure to achieve a haematological or cytogenetic response to ␣IFN places patients with CML in a prognostic group with a relatively poor outcome. Improved therapies are therefore required for subjects who are fit enough to tolerate a bone marrow transplant, but lack a suitable donor and fail to obtain a favourable cytogenetic response to ␣IFN.
The purpose of this study was to prospectively evaluate the feasibility, efficacy and toxicity of high-dose chemo-therapy with peripheral blood progenitor cell rescue, specifically for patients with CML failing to achieve a major cytogenetic response to ␣IFN. Patients were transplanted with substantially Ph-negative progenitor cells after disease cytoreduction. All patients were then placed back on ␣IFN in an attempt to achieve, or maintain, Ph-negative haemopoiesis. As prior exposure to ␣IFN may damage stem cells and delay engraftment following subsequent transplant, collection of the stem cells was performed before exposure to ␣IFN where possible.
Patients and methods

Patients and mobilisation protocol
Patients with a diagnosis of CML in first chronic phase who were not eligible for, or refused, allogeneic BMT were recruited to the study. Patients previously untreated with interferon underwent a buffy coat harvest by leukapheresis if their white blood cell count (WCC) was Ͼ50 ϫ 10 9 /l and were then treated with oral hydroxyurea. A progenitor cell harvest was performed once the WCC had been under control for 4 to 6 weeks. Patients who had been previously treated with ␣IFN, but had failed to obtain a major cytogenetic response (р35% Ph-positive marrow) or had a cytogenetic relapse following an initial response, proceeded to harvest after ␣IFN therapy had been stopped for a minimum of 8 weeks. Risk score at diagnosis was calculated using the new prognostic score (modified Sokal score) for patients with CML treated with ␣IFN. 15 
Cytogenetic analysis
Cytogenetic analysis was performed using conventional G banding, with analysis of 100 metaphases from both peripheral blood derived, or bone marrow cells. Nested RT-PCR was performed as per method of Hughes et al.
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Progression to transplant
Patients who had not previously been exposed to ␣IFN (protocol 1) were all given a therapeutic trial of ␣IFN following collection of progenitor cells. These patients proceeded to high-dose therapy and autologous progenitor cell rescue if they were intolerant of ␣IFN, or failed to achieve a complete or major cytogenetic response (Ͻ35% Ph-positive metaphases in bone marrow) after at least 12 months therapy with ␣IFN. Patients who, after 12 months on ␣IFN, demonstrated a minor cytogenetic response, continued with ␣IFN for a further 6 months prior to evaluation. Patients previously exposed to ␣IFN (protocol 2) who had failed to achieve or maintain a major cytogenetic response proceeded to autologous progenitor cell transplant as soon as was feasible.
Transplant methodology
The conditioning therapy consisted of standard busulphan 16 mg/kg over 4 days and cyclophosphamide 120 mg/kg over 2 days. Stem cell rescue was performed on day 0, 1 day after the last day of cyclophosphamide. ␣IFN was restarted when neutrophils were Ͼ2.0 ϫ 10 9 /l and platelets were Ͼ100 ϫ 10 9 /l. A bone marrow aspirate and a trephine were performed 3 months post PBSCT and samples sent for cytogenetic analysis. Marrow cytogenetics were re-checked every 6 months thereafter.
Statistical analysis
Survival curves were estimated by the method of Kaplan and Meier using Statistica software (StatSoft Inc (1997) Statistica for windows, Tulsa, OK, USA).
Results
Study population
From October 1993 to March 1999, 29 patients entered the study (19 males; 10 females). Thirteen (45%) patients had been previously treated with ␣IFN and 16 (55%) had not. The median age of the patients was 46 years (range 20-64). The median time from diagnosis to entry into the study for all patients was 7 months (range 2-78). The median time from diagnosis to study entry for patients in protocol 1 (no previous exposure to ␣IFN) was 5 months (range 2-22) and for patients in protocol 2 was 24 (range 4-78) months, respectively. Twenty-five (86%) patients were in chronic phase at the time of harvest and four (14%) patients were in semi-controlled accelerating phase. Patient characteristics are summarised in Table 1 . Harvest data and early outcome for four patients has been previously reported. 7, 9 Harvest data A total of 37 harvests were performed on 29 patients. One hundred and thirteen leukaphereses were performed overall, starting at a median of 16 days (range 12-35) from the last day of chemotherapy. The median WCC at the time of first harvest was 1.60 ϫ 
Cytogenetic analysis
The degree of Ph-negativity in PBPC collections varied considerably. In 9/29 (31%) patients all collected stem cells were Ph-negative and 15/29 (52%) all collections were substantially (Ͼ95%) Ph-negative. The likelihood of Ph-negative phereses decreased with increasing number of phereses performed, but did not correlate with total WCC at the time of pheresis (P ϭ 0.22). The proportion of patients from whom sufficient numbers of Ph-negative stem cells were obtained was similar between the groups who had, or had not received prior IFN (protocol 1 ϭ 9/16 patients with у95% Ph-negativity and protocol 2 ϭ 9/13 patients with у95% Ph-negativity). All phereses were positive for bcrabl by RT-PCR.
Eight patients required a second harvest either because the collections were substantially Ph-positive (n ϭ 5), or because of failure to collect adequate numbers of cells (n ϭ 4). Of these eight patients, five went on to have successful second harvests.
Harvest tolerability
Patients spent a median of 25 days (range 13-59) in hospital for the harvest period. All 29 patients experienced haematological toxicity (grade у3). Twenty-four (83%) patients developed a fever following chemotherapy and 12 (41%) patients developed an infection that required treatment with intravenous antibiotics. Four (14%) patients developed proven or suspected fungal infections and were treated with AmBisome (NeXstar Pharmaceuticals, Cambridge, UK). One developed a Staphylococcus aureus sepsis with an infected right atrial thrombus requiring surgical Bone Marrow Transplantation removal. GI toxicity (grade 1-3) was experienced in 12 (41%) patients. Skin rashes (grade 1-2) associated with drug therapy occurred in five (17%) patients. Other nonhaematological adverse events included headache (7%) and grade 1-3 mucositis (19%). Four (10%) patients experienced reactions considered to be related to treatment with G-CSF (fever, bone pain and rash). There was no procedure-related mortality or toxic death related to chemotherapy.
Transplant outcome
To date, 15 patients (10 male, five female), with a median age of 45 years (range 25-59) have proceeded to PBSCT. Nine of the 13 patients who had failed to respond to prior ␣IFN proceeded to stem cell transplantation as soon as was feasible. Three patients were not transplanted because their collections were substantially Ph-positive and one patient refused to undergo the procedure and was lost to follow-up.
Six of the newly diagnosed patients were transplanted after failing to achieve a cytogenetic response after a minimum of 6 months on ␣IFN, post harvest. All patients were in chronic phase at the time of transplant. Ten patients have not been transplanted at the time of writing. Five had substantially Ph-positive collections; two were controlled with IFN post harvest (one has since undergone a MUD) and three remain on a trial of IFN post harvest.
The median Ph-negativity of stem cells transplanted was 98% (range 61-100) with 47% of patients receiving 100% Ph-negative transplants. The median numbers of MNCs and Cytogenetic analysis of bone marrow was informative in 11/15 patients when performed 3 months following transplant. This demonstrated one patient with 100% Ph-negativity; seven patients with Ph-negativity of 31, 40, 50, 58, 65, 70 and 80% and three patients with 100% Ph-positivity. Six of 15 patients remain partially Ph-negative and one patient has had a major cytogenetic response (Ͼ90% Phnegativity) to ␣IFN, persisting at 23 months following PBSCT (see Table 2 ).
At median follow-up of 2.3 years post transplant, 10 of the 15 autografted patients remain alive and most are in chronic phase. Four patients died of disease progression and one died from incidental trauma. This death has not been censored from the survival curves, although the patient remained in chronic phase at the time of his death. The majority of patients are maintained on ␣IFN therapy with or without hydroxyurea. Overall survival for all 29 patients at 5 years from diagnosis is 70% and median survival 7.3 years (Figure 1) . Survival for IFN non-responders who were transplanted is 74% at 5 years from diagnosis ( Figure  2 ) and 75% at 3 years from transplant ( Figure 3 ). Although the numbers are small, revised Sokal risk score 15 had no obvious impact on survival in this protocol (Figure 4) .
Transplant toxicity
There were no transplant-related deaths. GI toxicity (grade у3) was experienced in 13 (87%) patients and seven (47%) patients developed moderate to severe mucositis. One patient developed an oesophageal ulcer which significantly prolonged his stay in hospital following PBSCT. Eleven (73%) patients developed a bacterial infection in the posttransplant period and all required treatment with intravenous antibiotics. One patient developed fungal pneumonia. One patient had reversible myocardial ischemia and rapid atrial fibrillation and another developed veno-occlusive disease (VOD) of the liver on day 19 having regenerated her WCC. Despite being thrombocytopenic and platelet refractory at this stage, she did not develop bleeding
Bone Marrow Transplantation problems and had a rapid resolution of her encephalopathy. She was discharged on day 38 post transplant.
Discussion
Administration of G-CSF following cytoreductive chemotherapy can result in the mobilisation of residual Ph-negative haemopoietic progenitor cells. Recent studies have shown that autologous progenitor cell rescue with Ph-negative cells after myeloablative chemotherapy may induce prolonged periods of haematologic and cytogenetic remission, and may be associated with prolonged survival. 8, 10, 14, 18 In this study we report the outcome of several years follow-up of patients with CML undergoing high-dose chemotherapy and autologous progenitor cell rescue using progenitor cells which were completely, or substantially, Ph negative by conventional cytogenetics. All subjects undergoing high-dose therapy had failed to achieve a major cytogenetic response on ␣IFN and would have a relatively poor outcome independently of Sokal risk score. All patients were placed back on ␣IFN following stem cell rescue in an attempt to achieve or maintain Ph-negative haemopoiesis.
We have confirmed that Ph-negative cells can be successfully collected from the peripheral blood of patients with CML and can be used for subsequent autologous transplant after myeloablation. Sufficient numbers of CD34 ϩ cells and MNCs to proceed safely to transplantation were collected in 90% and 97% of patients respectively, which compares favourably with other reported studies. [7] [8] [9] [10] 19 Phnegative stem cells were also successfully mobilised in the majority of patients. 9/29 (31%) collections were all Phnegative and 15/29 (52%) collections were substantially (Ͼ95%) Ph-negative. Although the first harvest failed in eight patients, five of these patients went on to have successful second harvests following re-induction with chemotherapy.
The actual timing of the harvest was influenced by the white cell count and the yield of CD34 ϩ cells increased as the white cell count regenerated after chemotherapy. However, we found no correlation between white cell count at the time of harvest and the likelihood of collecting Ph-negative cells. Earlier phereses were more likely to be Ph-negative, consistent with the hypothesis that negative cells either mobilize earlier, or Ph-positive progenitors are more sensitive to chemotherapy and as a result, take longer to regenerate. Continuing phereses in order to obtain more cells was therefore self-limiting because of the increase in Phpositivity of the pheresis product.
Previous reports have shown a significant difference in the PBSC harvest between patients who had not been treated with ␣IFN and were mobilised in the first few weeks after diagnosis (with WBC controlled by hydroxyurea) and patients who had received ␣IFN for Ͼ1 year. 8, 19 We found no obvious disadvantage in harvesting cells after prior exposure to ␣IFN, providing an adequate IFN-free rest period was used -however, our numbers are comparatively small. There was also no evidence that the percentage of Ph-negative stem cells harvested was influenced by time from diagnosis, or by revised Sokal score. 15 We have confirmed that autologous transplantation with Ph-negative cells, and subsequent ␣IFN maintenance, in patients failing to achieve an initial response to ␣IFN can induce a cytogenetic response post PBSCT. Clearly intensive chemotherapy alone, without progenitor cell rescue, may produce transient Ph-negative haemopoiesis, but it is rarely durable. Moreover, it can result in encouraging survival times in an otherwise relatively poor risk group of patients as survival for patients not responding to ␣IFN is consistently lower than in interferon responders. [11] [12] [13] 20 Median survival for patients failing to achieve a major cytogenetic response to ␣IFN, irrespective of age and other risk factors, varies from 3.5 to 5.5 years. The patients in our series did not differ significantly from these series in terms of median age or modified Sokal score.
Actuarial survival for patients in our series at 3.5 years post autograft is 75%. This is comparable to the 87% survival reported by the Genoa group. 10 Survival from diagnosis for autografted patients is 74% at 5 years; again, this compares favourably with other similar studies.
9,10 The survival durations, on crude observation, compare favourably with those reported for patients failing to respond to ␣IFN who do not undergo autologous transplantation. 13 Survival in our series also compares favourably with other studies of autologous transplantation in CML using unmanipulated progenitors. Five-year survival following autologous transplantation with unmanipulated buffy coat or bone marrow in unselected patients varies from 55 to 60%. 4, 6 These patients have not been selected by previous exposure to ␣IFN, making direct comparison difficult. The Vancouver group have achieved significantly better results with in vitro purging, although at the expense of delayed neutrophil engraftment (29 days vs 18 days). 5 These data suggest that in vivo or ex vivo purging of Ph-positive progenitors prior to stem cell rescue does confer a survival benefit.
Overall survival for all 29 patients in this series at 5 years from diagnosis is 70% and median survival 7.3 years. However, these data need to be considered independently as they contain patients who may have selected themselves out as good responders to ␣IFN and therefore may never need a transplant. Interestingly, the revised Sokal risk score at diagnosis had no obvious impact on survival in this protocol, although the numbers are small.
The majority of patients who were transplanted are alive and remain stable on standard therapy with a median follow-up of 4.7 years from diagnosis. The majority of patients experienced a brief period of conversion to partial or complete Philadelphia negativity following autografting. One patient has had a major cytogenetic response (Ͼ90% Ph-negativity) to ␣IFN, persisting 23 months post PBSCT, and two achieved a major response. The non-sustainability of a durable cytogenetic remission following PBSCT is in accordance with other studies, although the Vancouver group have shown patients to continue with predominantly Ph-negative haematopoiesis for more than 3 years followBone Marrow Transplantation ing autografting with cultured marrow. 5 Carella's group was able to restore and maintain a major or complete cytogenetic response in greater than 50% of their patient population. 10 In conclusion, PBSCT could be an option for patients who are ineligible for allogeneic transplantation and may prolong chronic phase. The procedure is reasonably well tolerated and patients not responding to ␣IFN may be induced into Ph-negativity with PBSCT, although this is not sustainable in the majority of patients. Further studies are needed to investigate more effective purging techniques in order to reduce contamination with Ph-positive cells during transplant. Another option is to improve post-transplant maintenance by using pegylated interferon, cytarabine or even STI571.
